SEQUOIA
May 6, 2026
Zanubrutinib as an effective 1st line treatment for CLL, irrespective of del(17p) status
At MediMix, we are dedicated to keeping Belgian healthcare professionals at the forefront of medicine. Our team brings you high-value insights from leading congresses worldwide, across key disease areas including hematology. In collaboration with Belgian and international experts, we transform the latest data into practical knowledge.
Now live
Coming soon
Now live
Past congresses
Latest publications
SEQUOIA & ALPINE
May 6, 2026
Zanubrutinib in the treatment of chronic lymphocytic leukemia Six-year results from
SEQUOIA & ALPINE with Long Term Extension
Clinical benefit of luspatercept in ESA-naive patients with very low-, low-, or intermediate-risk MDS: post-hoc data from COMMANDS
January 12, 2026
At ASH 2025, Prof Dr Valeria Santini presented the results of an ad hoc analysis of the COMMANDS trial focusing on clinically meaningful predictors of response to first-line therapy in
Highlights in Multiple Myeloma
December 19, 2025
In this video, Dr Marie Vercruyssen, hematologist at the Institut Jules Bordet in Brussels shares the key takeaways from 4 presentations related to multiple myeloma (MM) presented at ASH 2025.
Overall survival in mCRC patients with persistent chemotherapy-induced thrombocytopenia
December 19, 2025
In this video, Prof Hanny Al-Samkari, hematologist and clinical investigator, summarized findings from a poster presented at ASH 2025 examining overall survival (OS) in patients with metastatic colorectal cancer (mCRC)
BVd or BPd for functional high-risk MM: subgroup data from DREAMM-7 & DREAMM-8
December 19, 2025
In this video, Prof Vania Hungria, hematologist, summarizes the results from a subgroup analysis of the phase III DREAMM-7 and DREAMM-8 studies, evaluating belantamab mafodotin–based combinations in patients with relapsed
Isatuximab-Rd vs. Rd induction, followed by isa-R vs. R maintenance in very elderly patients with NDMM: results of AGMT-MM04
December 19, 2025
At ASH 2025, Prof Heinz Ludwig, haematologist presented a poster describing the results of a randomized phase II AGMT-MM04 study. This trial evaluated the efficacy and safety of isatuximab plus
Subcutaneous blinatumomab for relapsed/refractory ALL
December 19, 2025
At the 2025 American Society of Hematology (ASH) Annual Meeting, Prof Elias Jabbour, hematologist, presented updated results from a phase 1b study evaluating subcutaneous blinatumomab in patients with relapsed or